Switch theme
Sign up to access all valuation multiples
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.
2006
234
Last FY Revenue $22.0M
Last FY EBITDA -$38.5M
$21.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Novacyt achieved revenue of $22.0M and an EBITDA of -$38.5M.
Novacyt expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novacyt valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $22.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $36.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 163% | XXX | XXX | XXX |
| EBITDA | XXX | -$38.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -175% | XXX | XXX | XXX |
| EBIT | XXX | -$18.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -85% | XXX | XXX | XXX |
| Net Profit | XXX | -$46.9M | XXX | XXX | XXX |
| Net Margin | XXX | -213% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Novacyt's stock price is EUR 1 (or $1).
Novacyt has current market cap of EUR 41.0M (or $46.0M), and EV of EUR 18.7M (or $21.1M).
See Novacyt trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21.1M | $46.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Novacyt has market cap of $46.0M and EV of $21.1M.
Novacyt's trades at 1.0x EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Novacyt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novacyt's P/E ratio is not available.
See valuation multiples for Novacyt and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46.0M | XXX | $46.0M | XXX | XXX | XXX |
| EV (current) | $21.1M | XXX | $21.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNovacyt's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Novacyt's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novacyt's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Novacyt and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -175% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 248% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novacyt acquired XXX companies to date.
Last acquisition by Novacyt was XXXXXXXX, XXXXX XXXXX XXXXXX . Novacyt acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Novacyt founded? | Novacyt was founded in 2006. |
| Where is Novacyt headquartered? | Novacyt is headquartered in France. |
| How many employees does Novacyt have? | As of today, Novacyt has 234 employees. |
| Who is the CEO of Novacyt? | Novacyt's CEO is Mr. Lyn Dafydd Rees. |
| Is Novacyt publicy listed? | Yes, Novacyt is a public company listed on PAR. |
| What is the stock symbol of Novacyt? | Novacyt trades under ALNOV ticker. |
| When did Novacyt go public? | Novacyt went public in 2012. |
| Who are competitors of Novacyt? | Similar companies to Novacyt include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Novacyt? | Novacyt's current market cap is $46.0M |
| Is Novacyt profitable? | Yes, Novacyt is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
